Growth ⏱ Half-life: Approximately 1-2 hours. Approved Abroad

GHRP-2

Growth Hormone Releasing Peptide-2

Updated March 15, 2026

Evidence at a Glance

Regulatory statusApproved Abroad
Approved in Japan (2004, as pralmorelin) as a single-dose GH-deficiency diagnostic; not FDA-approved.
Human evidenceModerate
Animal evidenceExtensive

GHRP-2 (pralmorelin) is approved in Japan only as a GH-stimulation diagnostic and has human GH-secretion data, but no approval for therapeutic or physique use.

What the research does not support

  • It is not FDA-approved and is not a validated anti-aging or bodybuilding drug; its only regulatory approval is as a one-time diagnostic test in Japan.
  • It does not release GH selectively — it also raises appetite, cortisol and prolactin.
  • Long-term efficacy and safety for cosmetic, athletic or wellness use have not been established, and it is banned in sport.
Half-Life
Approximately 1-2 hours.
Mol. Weight
817.97 g/mol

What is GHRP-2?

GHRP-2 is a synthetic hexapeptide growth hormone secretagogue often considered the balanced choice in the GHRP family — more potent than GHRP-6 with better selectivity, though not as clean as Ipamorelin.

Research Applications

GH secretagogue research, appetite and feeding behavior studies, pituitary function assessment, and comparative GH-axis pharmacology.

Dosage Information (Research Use)

100-300 mcg subcutaneously, 1-3 times daily. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution.

Half-Life & Pharmacokinetics

Approximately 1-2 hours.

Reported Observations in Literature

Moderate cortisol and prolactin elevation, increased appetite (less than GHRP-6), water retention, drowsiness.

Key Research References

  • Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cell Mol Life Sci. 1998

How GHRP-2 Works

GHRP-2 acts on the ghrelin/GHS receptor to stimulate pituitary GH release. Produces a more robust GH response than GHRP-6 with less appetite stimulation, but more cortisol/prolactin elevation than Ipamorelin. Considered the strongest clinically-studied GHRP after Hexarelin.

Research Findings

Extensive pharmacological data available. Often used as a reference standard in GHRP comparative studies. Good balance of potency and selectivity.

Dosage & Administration

100-300 mcg subcutaneously, 1-3 times daily. Research use only.

Safety & Side Effects

Moderate cortisol and prolactin elevation, increased appetite (less than GHRP-6), water retention, drowsiness.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular Weight 817.97 g/mol
Half-Life Approximately 1-2 hours.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cell Mol Life Sci. 1998

Related Peptides

View all →
CJC-1295
Growth
Growth hormone releasing hormone analog that stimulates pulsatile GH secretion for sustained elevation of growth hormone and IGF-1.
View Profile → Buy Now
CJC-1295 DAC
Growth
Long-acting GHRH analog with albumin-binding DAC extension for sustained GH elevation over 8+ days per injection.
View Profile → Buy Now
MK-677
Growth
Non-peptide oral ghrelin mimetic that provides sustained GH and IGF-1 elevation over 24 hours with once-daily oral dosing.
View Profile →